[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546763":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":7,"responsibleParty":13,"collaborators":7,"id":15,"slug":16,"hasResults":17,"nctId":18,"briefTitle":19,"officialTitle":20,"acronym":21,"eligibilityCriteria":22,"healthyVolunteers":17,"sex":23,"minAge":24,"maxAge":7,"enrollmentInfo":25,"targetDuration":28,"studyType":29,"phases":7,"briefSummary":30,"conditions":31,"keywords":7,"overallStatus":33,"whyStopped":7,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":7},{"fullName":5,"class":6},"OncoSil Medical Limited","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DEVICE","OncoSil","Intra-tumoural implantation",{"type":14,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100546763","oncosil-pancreatic-cancer-post-marketing-clinical-registry---italy-100546763",false,"NCT06399172","OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy","OncoSil Pancreatic Cancer Post-marketing Clinical Registry Italy","OSPRItaly","Inclusion Criteria:\n\n1. Patients who are eligible for and undergo OncoSil™ implantation at an eligible treatment facility according to the approved OncoSil™ System Instructions for Use (IFU), as part of their clinical care.\n2. Patients who have completed and signed the Patient Informed Consent Form (PICF) for the OSPRItaly Patient Registry.\n\nExclusion Criteria:\n\n1. Patients participating in an interventional clinical study (company or investigator-sponsored).\n2. Use of an investigational agent at the time of enrolment.","ALL","18 Years",{"count":26,"type":27},50,"ESTIMATED","1 Year","OBSERVATIONAL","The OSPRItaly Patient Registry has been developed to assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination with gemcitabine-based chemotherapy, within a real-world observational registry.",[32],"Locally Advanced Pancreatic Adenocarcinoma","NOT_YET_RECRUITING","2024-05-01",{"date":36,"type":37},"2024-05-03","ACTUAL",{"date":39,"type":27},"2024-05-30",{"date":41,"type":27},"2029-10-30",{"name":5,"class":6}]